​

Chengdu Kanghua Biological Products Co., Ltd.

SZSE:300841 Stock Report

Market Cap: CN¥9.4b

Chengdu Kanghua Biological Products (300841) Stock Overview

Chengdu Kanghua Biological Products Co., Ltd. More details

300841 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Rewards

Price-To-Earnings ratio (34.7x) is below the CN market (40.6x)

Earnings are forecast to grow 30.35% per year

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

Volatile share price over the past 3 months compared to the CN market

Profit margins (21.4%) are lower than last year (34.4%)


300841 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Chengdu Kanghua Biological Products Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Chengdu Kanghua Biological Products
Historical stock prices
Current Share PriceCN¥72.01
52 Week HighCN¥79.00
52 Week LowCN¥44.01
Beta2.43
1 Month Change23.09%
3 Month Change14.08%
1 Year Change38.27%
3 Year Change-29.14%
5 Year Change-76.47%
Change since IPO59.90%

Recent News & Updates

Recent updates

The Market Doesn't Like What It Sees From Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Earnings Yet

Sep 13
The Market Doesn't Like What It Sees From Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Earnings Yet

We Think Chengdu Kanghua Biological Products (SZSE:300841) Can Stay On Top Of Its Debt

Jun 26
We Think Chengdu Kanghua Biological Products (SZSE:300841) Can Stay On Top Of Its Debt

Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Prospects Need A Boost To Lift Shares

Feb 27
Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Prospects Need A Boost To Lift Shares

Shareholder Returns

300841CN BiotechsCN Market
7D16.2%3.7%0.6%
1Y38.3%15.8%25.3%

Return vs Industry: 300841 exceeded the CN Biotechs industry which returned 15.8% over the past year.

Return vs Market: 300841 exceeded the CN Market which returned 25.3% over the past year.

Price Volatility

Is 300841's price volatile compared to industry and market?
300841 volatility
300841 Average Weekly Movement8.1%
Biotechs Industry Average Movement4.9%
Market Average Movement4.9%
10% most volatile stocks in CN Market8.6%
10% least volatile stocks in CN Market2.8%

Stable Share Price: 300841's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 300841's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2004620Hongbo Wuwww.kangh.com

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines.

Chengdu Kanghua Biological Products Co., Ltd. Fundamentals Summary

How do Chengdu Kanghua Biological Products's earnings and revenue compare to its market cap?
300841 fundamental statistics
Market capCN¥9.36b
Earnings (TTM)CN¥269.89m
Revenue (TTM)CN¥1.26b
34.7x
P/E Ratio
7.4x
P/S Ratio

Is 300841 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300841 income statement (TTM)
RevenueCN¥1.26b
Cost of RevenueCN¥80.13m
Gross ProfitCN¥1.18b
Other ExpensesCN¥908.43m
EarningsCN¥269.89m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 26, 2025

Earnings per share (EPS)2.08
Gross Margin93.63%
Net Profit Margin21.45%
Debt/Equity Ratio4.7%

How did 300841 perform over the long term?

See historical performance and comparison

Dividends

1.4%
Current Dividend Yield
48%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/17 21:34
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chengdu Kanghua Biological Products Co., Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhu ChenCitic Securities Co., Ltd.
Yizhang ZhuCitic Securities Co., Ltd.
Wentao LiCitic Securities Co., Ltd.